ProQR Therapeutics (PRQR) News Today $3.67 +0.07 (+1.94%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving Average - Time to Sell?ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above Fifty Day Moving Average - Time to Sell?November 21 at 4:11 AM | marketbeat.comEquities Analysts Set Expectations for PRQR FY2024 EarningsNovember 15, 2024 | americanbankingnews.comWhat is Chardan Capital's Forecast for PRQR FY2024 Earnings?ProQR Therapeutics (NASDAQ:PRQR - Free Report) - Chardan Capital decreased their FY2024 earnings per share estimates for shares of ProQR Therapeutics in a report released on Sunday, November 10th. Chardan Capital analyst K. Nakae now forecasts that the biopharmaceutical company will earn ($0.31)November 13, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Price Target Raised to $10.00HC Wainwright raised their target price on ProQR Therapeutics from $5.00 to $10.00 and gave the stock a "buy" rating in a research report on Friday.November 8, 2024 | marketbeat.comProQR Therapeutics price target raised to $10 from $5 at H.C. WainwrightNovember 8, 2024 | tipranks.comProQR Announces Third Quarter 2024 Operating and Financial ResultsNovember 8, 2024 | markets.businessinsider.comProQR Therapeutics reports Q3 EPS (EUR 0.10) vs. (EUR 0.07) last yearNovember 7, 2024 | markets.businessinsider.comProQR Therapeutics Shows Revenue Growth Amid Financial ChallengesNovember 7, 2024 | markets.businessinsider.comProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Above Fifty Day Moving Average - Here's WhyProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above 50 Day Moving Average - Time to Sell?November 6, 2024 | marketbeat.comRaymond James Upgrades ProQR Therapeutics N.V. (PRQR)October 29, 2024 | msn.comProQR Therapeutics (NASDAQ:PRQR) Upgraded to Strong-Buy at Raymond JamesRaymond James upgraded ProQR Therapeutics from an "outperform" rating to a "strong-buy" rating and increased their target price for the stock from $6.00 to $14.00 in a research report on Tuesday.October 29, 2024 | marketbeat.comProQR Announces Closing of Underwritten Public Offering and Concurrent Private PlacementOctober 25, 2024 | globenewswire.comProQR Therapeutics 18M share Spot Secondary priced at $3.50October 24, 2024 | markets.businessinsider.comProQR Therapeutics announces ordinary shares offering, no amount givenOctober 23, 2024 | markets.businessinsider.comProQR Prices $75 Million Underwritten Public Offering and Concurrent Private PlacementOctober 22, 2024 | globenewswire.comProQR Announces Proposed Underwritten Public Offering of Ordinary SharesOctober 22, 2024 | globenewswire.comProQR Therapeutics (NASDAQ:PRQR) shareholder returns have been solid, earning 231% in 1 yearOctober 21, 2024 | finance.yahoo.comProQR Therapeutics (NASDAQ:PRQR) Stock Quotes, Forecast and News SummaryOctober 17, 2024 | benzinga.comProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics SocietyOctober 7, 2024 | globenewswire.comProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below Two Hundred Day Moving Average - Here's WhyProQR Therapeutics (NASDAQ:PRQR) Share Price Crosses Below 200 Day Moving Average - Here's WhyOctober 5, 2024 | marketbeat.comAutolus Therapeutics plc (6A3A.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare ConferenceSeptember 10, 2024 | globenewswire.comProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above 50-Day Moving Average of $1.90ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Above 50-Day Moving Average of $1.90September 10, 2024 | marketbeat.comPRQR ProQR Therapeutics N.V.September 4, 2024 | seekingalpha.comProQR Therapeutics Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagAugust 12, 2024 | finance.yahoo.comBuy Rating Affirmed: ProQR’s Promising RNA-Editing Clinical and Preclinical ProspectsAugust 9, 2024 | markets.businessinsider.comProQR GAAP EPS of -€0.03, revenue of €6.31MAugust 8, 2024 | msn.comProQR Announces Second Quarter 2024 Operating and Financial ResultsAugust 8, 2024 | markets.businessinsider.comProQR Therapeutics (NASDAQ:PRQR) Shares Pass Below Two Hundred Day Moving Average of $2.01ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below 200 Day Moving Average of $2.01July 18, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Short Interest UpdateProQR Therapeutics (NASDAQ:PRQR - Get Free Report) was the target of a large decrease in short interest during the month of June. As of June 15th, there was short interest totalling 196,600 shares, a decrease of 18.5% from the May 31st total of 241,200 shares. Based on an average daily trading volume, of 124,600 shares, the days-to-cover ratio is presently 1.6 days. Approximately 0.4% of the company's stock are short sold.June 29, 2024 | marketbeat.comStockNews.com Upgrades ProQR Therapeutics (NASDAQ:PRQR) to "Hold"StockNews.com upgraded shares of ProQR Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday.June 29, 2024 | marketbeat.comStockNews.com Lowers ProQR Therapeutics (NASDAQ:PRQR) to SellStockNews.com downgraded ProQR Therapeutics from a "hold" rating to a "sell" rating in a report on Friday.June 21, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Raised to "Hold" at StockNews.comStockNews.com upgraded ProQR Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday.June 13, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Rating Lowered to Sell at StockNews.comStockNews.com downgraded shares of ProQR Therapeutics from a "hold" rating to a "sell" rating in a report on Wednesday.June 5, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Shares Pass Above 50 Day Moving Average of $2.02ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Above 50-Day Moving Average of $2.02June 5, 2024 | marketbeat.comShareholders in ProQR Therapeutics (NASDAQ:PRQR) are in the red if they invested five years agoMay 13, 2024 | finance.yahoo.comProQR Therapeutics (NASDAQ:PRQR) Cut to "Sell" at StockNews.comStockNews.com downgraded shares of ProQR Therapeutics from a "hold" rating to a "sell" rating in a report on Friday.May 11, 2024 | marketbeat.comProQR’s Axiomer Platform Technology Shows Promise: Analyst Maintains Buy Rating on Robust Editing Efficacy and Clinical Development PotentialMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for ProQR on Promising RNA Editing Technology and Solid Financial FootingMay 10, 2024 | markets.businessinsider.comProQR Therapeutics' (PRQR) "Buy" Rating Reaffirmed at Chardan CapitalChardan Capital reiterated a "buy" rating and issued a $2.50 target price on shares of ProQR Therapeutics in a report on Friday.May 10, 2024 | marketbeat.comProQR Therapeutics N.V.: ProQR Announces First Quarter 2024 Operating and Financial ResultsMay 9, 2024 | finanznachrichten.deProQR Announces First Quarter 2024 Operating and Financial ResultsMay 9, 2024 | globenewswire.comBuy Recommendation on ProQR’s Innovative RNA Editing Platform and Promising Clinical ProspectsMay 8, 2024 | markets.businessinsider.comProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer(TM) RNA Editing Program Targeting NTCP for Cholestatic DiseasesMay 8, 2024 | stockhouse.comProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic DiseasesMay 8, 2024 | finance.yahoo.comProQR Highlights Upcoming Presentations on Axiomer(TM) RNA Editing at ASGCT 27th Annual MeetingApril 24, 2024 | stockhouse.comProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024April 23, 2024 | globenewswire.comProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual MeetingApril 22, 2024 | finance.yahoo.comProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual MeetingApril 22, 2024 | globenewswire.comProQR retains key patent for RNA editing technologyApril 21, 2024 | uk.investing.com Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Email Address Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development… YES, I WANT THE #1 CRYPTO NOW PRQR Media Mentions By Week PRQR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRQR News Sentiment▼-0.290.46▲Average Medical News Sentiment PRQR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRQR Articles This Week▼31▲PRQR Articles Average Week Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ANI Pharmaceuticals News Today Ardelyx News Today Applied Therapeutics News Today Avadel Pharmaceuticals News Today Zymeworks News Today Septerna News Today Cogent Biosciences News Today Bicara Therapeutics News Today Bicycle Therapeutics News Today Phibro Animal Health News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRQR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share ProQR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
